Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice. McCuaig JM, et al. Among authors: provencher d. J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24. J Med Genet. 2018. PMID: 30042185 Free PMC article. Review.
Management of squamous cell cancer of the vulva.
Faught W; SOGC/GOC/SCC POLICY AND PRACTICE GUIDELINES COMMITTEE MEMBERS:. Faught W, et al. J Obstet Gynaecol Can. 2006 Jul;28(7):640-645. doi: 10.1016/S1701-2163(16)32197-1. J Obstet Gynaecol Can. 2006. PMID: 16924782 English, French. No abstract available.
Global distribution and career outcomes of international fellows trained in Canadian gynecologic oncology programs.
Touhami O, De Guerke L, Teo Fortin LA, Foo J, Provencher D, Samouelian V, Cormier B, Lau S, Salvador S, Gotlieb W, Gilbert L, Laframboise S, Altman AD, Ghatage P, Brar H, Kwon J, Le T, Sebastianelli A, Fokom Domgue J, Plante M. Touhami O, et al. Among authors: provencher d. Gynecol Oncol Rep. 2024 Sep 16;56:101512. doi: 10.1016/j.gore.2024.101512. eCollection 2024 Dec. Gynecol Oncol Rep. 2024. PMID: 39386924 Free PMC article.
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
Gupta AA, Tinker A, Jonker D, Jamal R, Hirte H, Winquist EW, Chu Q, Kollmannsberger C, Wong R, Alcindor T, Nielsen TO, Tsao M, Cottrell TR, Provencher D, Hilton J, Krzyżanowska MK, Elser C, Hotte S, Sederias J, Zhang S, Tu W, Dancey J. Gupta AA, et al. Among authors: provencher d. EClinicalMedicine. 2024 Dec 10;79:102991. doi: 10.1016/j.eclinm.2024.102991. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39737219 Free PMC article.
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Graybill WS, Vergote I, Pothuri B, Anttila M, O'Malley DM, Lorusso D, Haggerty AF, Fabbro M, Chan JK, Heitz F, Willmott LJ, Bruchim I, Zhuo Y, Estévez-García P, Monk BJ, Denys H, Knudsen A, Tinker AV, Sánchez LM, Provencher D, Barretina-Ginesta MP, Hartman J, Booth DV, González-Martín A. Graybill WS, et al. Among authors: provencher d. J Comp Eff Res. 2025 Jan;14(1):e240133. doi: 10.57264/cer-2024-0133. Epub 2024 Dec 6. J Comp Eff Res. 2025. PMID: 39641537 Free PMC article.
Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol SA, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F. Fleury H, et al. Among authors: provencher d. Nat Commun. 2024 May 13;15(1):4011. doi: 10.1038/s41467-024-48270-9. Nat Commun. 2024. PMID: 38740764 Free PMC article. No abstract available.
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J, Felicetti B, Baines AJ, YoussefAgha A, Rojas-Espaillat L, Ortiz AG, Provencher D, Vázquez RM, Cortijo LG, Zeng X. Belotte J, et al. Among authors: provencher d. Trials. 2024 May 4;25(1):301. doi: 10.1186/s13063-024-08142-5. Trials. 2024. PMID: 38702828 Free PMC article.
Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
Sauriol SA, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, Oza AM, Lheureux S, Provencher DM, Mes-Masson AM. Sauriol SA, et al. Among authors: provencher dm. Sci Rep. 2024 May 1;14(1):10017. doi: 10.1038/s41598-024-60769-1. Sci Rep. 2024. PMID: 38693303 Free PMC article. No abstract available.
283 results